rapiplex

Formed in 2009, Biosensia is a science focused, venture backed business established specifically to develop and exploit this novel and proprietary technology, RapiPlex. Biosensia is interested in exploring product commercialisation under license agreement.

The company has core skills in immunology, biochemistry,  microbiology, physics, microfluidics, design engineering, software development and quality/regulatory affairs. Our aim is to make RapiPlex a method of choice for testing multiple analytes in a matter of minutes.

The Biosensia Team

Our management and advisory team have a proven track record
in taking novel products to successful commercialisation

Prof. Jim Walsh
Prof. Jim WalshExecutive Chairman
Jim joined Biosensia in 2009, he is non-executive director & CSO at Trinity Biotech (NASDAQ:TRIB) and has been a consultant to a range of healthcare companies. Previously Managing Director of Cambridge Diagnostics Ltd (Inverness Medical).
Niamh O’Luanaigh
Niamh O’LuanaighChief Operating Officer
Niamh joined Biosensia in 2011, having previously worked for BBInternational (Alere) for 11 years. Responsible for development of multiple rapid tests and esatblished BBI’s first site outside UK, in USA for development and manufacture of rapid tests.
Dr. Shane Moynihan
Dr. Shane MoynihanHead of Engineering
Shane joined Biosensia in 2009, Shane’s background is in optical system development. He previously worked at the Tyndall National Institue, Cork, Ireland. He holds a PhD in nanotechnology and optical instrumentation design.

Our Board Of Directors

Mark Horgan
Mark Horgan Non-Executive Director
Mark is a Venture Partner at Atlantic Bridge and has been involved in the venture capital industry since 2001. Prior to joining Atlantic Bridge in 2004, Mark was CEO of Mentor Capital, a venture capital firm he founded in 2001 that specialized in investing in and mentoring seed and early stage technology companies. Mark has a successful track record of investing in and growing technology companies and has sold numerous companies, including OMI, Firecomms and Nanotech, to international buyers since 1997.
Jennifer McMahon
Jennifer McMahonNon-Executive Director
Jennifer joined the team of Seroba Kernel in 2011. She graduated from UCD with an honours degree in Pharmacology in 2010. Jennifer then entered a masters degree programme in Biotechnology and Business to further her interest in the interface of biomedical science with commercialisation. Having placed first in her master’s degree in 2011, Jennifer then joined Seroba Kernel’s Investment Team as an Investment Analyst and was appointed Senior Analyst in 2014.
Vivian McGuire
Vivian McGuire Non-Executive Director
Vivian is General Partner and CEO of Street Capital Partners a venture capital company based in Dublin, Ireland. Prior to founding Street Capital Partners he was co-founder of Allen McGuire & Partners, a private equity investment company and before that he spent six years as VP with Goldman Sachs & Co.
James D. Merselis
James D. MerselisNon-Executive Director
Jim first joined Biosensia in 2012 as a non-executive director.  He is also a non-executive director at Trinity Biotech (NASDAQ: TRIB) and has been a consultant to a range of healthcare companies. Jim has more than thirty-six years’ experience in healthcare, with the first twenty-two years at Boehringer Mannheim Diagnostics (now Roche Diagnostics).  Mr. Merselis has since lead a number of healthcare diagnostic start-ups.  From 2002 to 2007, he served as President and CEO of HemoSense, Inc., a point-of-care diagnostics company providing patients and physicians with rapid test results to help manage the risk of stroke with the use of warfarin or Coumadin.  During this time he successfully took the company public (NASDAQ:HEM) followed two years later by its acquisition by Alere (NYSE: ALR).  His leadership at other start-ups included: Nexus Dx (now Samsung), Alverix, Inc. and Micronics, Inc. (now SONY).
Bill Boteler
Bill Boteler Non-Executive Director
Bill worked at Microbiological Associates (currently Lonsa) upon graduating from the University of Maryland. He became the head of R&D and Production of the diagnostic product line. During this time he obtained an MBA from Mount St Mary’s College. He was involved with the first ELISA product that obtained approval from the Food and Drug Administration (FDA). Over his career he has obtained close to 100 FDA approvals for diagnostic products, with many being the first through the FDA, such as assays for Lyme Disease and Helicobactor pylori. He left the company in 1993 to start his own company, Immuno Probe Inc. Immuno Probe has developed numerous diagnostic products, obtained FDA approval and licensed them out to diagnostic Companies for manufacture and sale. The company also produces and markets numerous ELISA products for the life science market in the area of lab animal diagnostics and drug discovery.
John O'Sullivan
John O'SullivanBoard Advisor
John is a Director of ACT Venture Capital and has been active in operating roles and venture investing for 20 years.  He is currently on the boards of Adeptra, S3 Group, Frontier Silicon & Novate Medical and works with the teams at Swrve, Digit Gaming, Biosensia, Worldnet, Storyful and Cloudium. Previously, he was on the board of Kymata (acquired by Alcatel), AGI Therapeutics plc (acquired by Vidara Therapeutics), Firecomms (acquired by ZJF Group) and Intense Photonics and was involved with a number of other ACT investments. Prior to joining ACT, John worked with a range of start-up companies through the state indigenous development agency, Enterprise Ireland.  John also he held a number of business and operating roles, with Misys plc, Kindle Banking Systems and KAO Info-systems. He graduated from University College Cork (UCC) with a degree in Commerce and also holds an ACCA Certified Diploma in Financial Management.  John is an Adjunct Fellow at the UCC Business School.